Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.